France’s Theravectys Attracts Wealthy Private Investors To Support HIV Vaccine Study
This article was originally published in The Pink Sheet Daily
Executive Summary
High-net-worth private investors, the military and fellow French companies have provided funding for a trio of early-stage French biotechs – Theravectys, Nosopharm and GamaMabs Pharma. VCs are nowhere to be seen.